Your browser doesn't support javascript.
Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients.
Fraser, Douglas D; Patel, Maitray A; Van Nynatten, Logan R; Martin, Claudio; Seney, Shannon L; Miller, Michael R; Daley, Mark; Slessarev, Marat; Cepinskas, Gediminas; Juneja, Ganeem K; Sabourin, Vanessa; Fox-Robichaud, Alison; Yeh, Calvin H; Kim, Paul Y; Badrnya, Sigrun; Oehler, Susanne; Miholits, Markus; Webb, Brian.
  • Fraser DD; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Patel MA; Pediatrics, Western University, London, ON, N6A 3K7, Canada.
  • Van Nynatten LR; Clinical Neurological Sciences, Western University, London, ON, N6A 3K7, Canada.
  • Martin C; Physiology & Pharmacology, Western University, London, ON, N6A 3K7, Canada.
  • Seney SL; Epidemiology, Western University, London, ON, N6A 3K7, Canada.
  • Miller MR; Medicine, Western University, London, ON, N6A 3K7, Canada.
  • Daley M; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Slessarev M; Medicine, Western University, London, ON, N6A 3K7, Canada.
  • Cepinskas G; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Juneja GK; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Sabourin V; Pediatrics, Western University, London, ON, N6A 3K7, Canada.
  • Fox-Robichaud A; Epidemiology, Western University, London, ON, N6A 3K7, Canada.
  • Yeh CH; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Kim PY; Medicine, Western University, London, ON, N6A 3K7, Canada.
  • Badrnya S; Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
  • Oehler S; Medical Biophysics, Western University, London, ON, N6A 3K7, Canada.
  • Miholits M; Medicine, McMaster University, Hamilton, ON, L8S 4L8, Canada.
  • Webb B; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, L8L 2X2, Canada.
Heliyon ; 9(1): e12704, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2165332
ABSTRACT
Critically ill patients infected with SARS-CoV-2 display adaptive immunity, but it is unknown if they develop cross-reactivity to variants of concern (VOCs). We profiled cross-immunity against SARS-CoV-2 VOCs in naturally infected, non-vaccinated, critically ill COVID-19 patients. Wave-1 patients (wild-type infection) were similar in demographics to Wave-3 patients (wild-type/alpha infection), but Wave-3 patients had higher illness severity. Wave-1 patients developed increasing neutralizing antibodies to all variants, as did patients during Wave-3. Wave-3 patients, when compared to Wave-1, developed more robust antibody responses, particularly for wild-type, alpha, beta and delta variants. Within Wave-3, neutralizing antibodies were significantly less to beta and gamma VOCs, as compared to wild-type, alpha and delta. Patients previously diagnosed with cancer or chronic obstructive pulmonary disease had significantly fewer neutralizing antibodies. Naturally infected ICU patients developed adaptive responses to all VOCs, with greater responses in those patients more likely to be infected with the alpha variant, versus wild-type.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: Heliyon Year: 2023 Document Type: Article Affiliation country: J.heliyon.2022.e12704

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: Heliyon Year: 2023 Document Type: Article Affiliation country: J.heliyon.2022.e12704